Commonwealth Equity Services LLC raised its holdings in Xometry, Inc. (NASDAQ:XMTR – Free Report) by 66.0% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 25,403 shares of the company’s stock after acquiring an additional 10,103 shares during the quarter. Commonwealth Equity Services LLC owned approximately 0.06% of Xometry worth $294,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. grew its position in shares of Xometry by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 304,341 shares of the company’s stock worth $10,929,000 after buying an additional 5,144 shares in the last quarter. Principal Financial Group Inc. bought a new position in shares of Xometry during the 4th quarter worth $709,000. Quest Partners LLC bought a new position in shares of Xometry during the 4th quarter worth $125,000. Austin Wealth Management LLC bought a new position in shares of Xometry during the 4th quarter worth $646,000. Finally, Wellington Management Group LLP bought a new position in shares of Xometry during the 4th quarter worth $21,165,000. Institutional investors own 97.31% of the company’s stock.
Xometry Trading Up 1.1 %
Xometry stock opened at $18.74 on Wednesday. The stock has a 50-day moving average of $17.14 and a two-hundred day moving average of $16.08. The company has a debt-to-equity ratio of 0.89, a quick ratio of 4.60 and a current ratio of 4.64. Xometry, Inc. has a one year low of $11.08 and a one year high of $38.74. The stock has a market cap of $864.36 million, a PE ratio of -13.78 and a beta of 0.58.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on the company. Citigroup dropped their price target on Xometry from $31.00 to $24.00 and set a “buy” rating on the stock in a research report on Tuesday, May 28th. JMP Securities restated a “market outperform” rating and set a $27.00 price objective on shares of Xometry in a research note on Thursday, September 19th. Finally, Cantor Fitzgerald decreased their price objective on Xometry from $13.00 to $12.00 and set an “underweight” rating for the company in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $22.14.
View Our Latest Research Report on Xometry
Insider Buying and Selling at Xometry
In other Xometry news, CTO Matthew Leibel sold 3,400 shares of the stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $18.45, for a total value of $62,730.00. Following the completion of the sale, the chief technology officer now directly owns 82,918 shares in the company, valued at $1,529,837.10. The transaction was disclosed in a document filed with the SEC, which is available at this link. Over the last ninety days, insiders sold 4,700 shares of company stock worth $78,018. 19.23% of the stock is owned by insiders.
Xometry Profile
Xometry, Inc operates an online marketplace that enables buyers to source custom-manufactured parts and assemblies in the United States and internationally. It provides computer numerical control manufacturing, sheet metal forming, and sheet cutting; 3D printing, including fused deposition modeling, direct metal laser sintering, PolyJet, stereolithography, selective laser sintering, binder jetting, carbon digital light synthesis, multi jet fusion, and lubricant sublayer photo-curing; and die casting, stamping, injection molding, urethane casting, tube cutting, and tube bending, as well as finishing services, rapid prototyping, and high-volume production services.
Featured Stories
- Five stocks we like better than Xometry
- What is Insider Trading? What You Can Learn from Insider Trading
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- With Risk Tolerance, One Size Does Not Fit All
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Xometry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xometry and related companies with MarketBeat.com's FREE daily email newsletter.